304,985 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired a new position in Cytek Biosciences, purchasing 304,985 shares valued at approximately $1.22 million, amounting to about 0.24% of the company's stock.
• Various hedge funds are actively adjusting their positions in Cytek, with 69.46% of the company's stock now owned by institutional investors.
• Analysts have recently revised their ratings on Cytek Biosciences, with Goldman Sachs lowering its target price from $3.50 to $3.00 and currently a consensus rating of "Hold" among research analysts.

Nuveen LLC bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 304,985 shares of the company's stock, valued at approximately $1,223,000. Nuveen LLC owned about 0.24% of Cytek Biosciences at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Aquatic Capital Management LLC bought a new position in Cytek Biosciences in the fourth quarter valued at about $25,000. US Bancorp DE raised its position in Cytek Biosciences by 9,698.2% in the first quarter. US Bancorp DE now owns 10,680 shares of the company's stock valued at $43,000 after purchasing an additional 10,571 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Cytek Biosciences in the first quarter valued at about $63,000. Corton Capital Inc. bought a new position in Cytek Biosciences in the first quarter valued at about $65,000. Finally, CWM LLC raised its position in Cytek Biosciences by 1,637.7% in the first quarter. CWM LLC now owns 18,020 shares of the company's stock valued at $72,000 after purchasing an additional 16,983 shares during the last quarter. 69.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CTKB has been the subject of several recent research reports. The Goldman Sachs Group decreased their price target on Cytek Biosciences from $3.50 to $3.00 and set a "sell" rating for the company in a research note on Monday, May 12th. TD Cowen cut Cytek Biosciences from a "buy" rating to a "hold" rating and set a $4.00 price target for the company. in a research note on Friday, May 9th. Finally, Morgan Stanley decreased their price target on Cytek Biosciences from $9.00 to $7.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cytek Biosciences presently has a consensus rating of "Hold" and an average price target of $5.60.

Cytek Biosciences Trading Up 1.0%

NASDAQ CTKB traded up $0.04 during trading hours on Friday, hitting $4.02. 713,443 shares of the company's stock were exchanged, compared to its average volume of 978,770. The stock has a 50-day simple moving average of $3.75 and a 200 day simple moving average of $3.70. Cytek Biosciences, Inc. has a 1-year low of $2.37 and a 1-year high of $7.63. The firm has a market cap of $511.42 million, a price-to-earnings ratio of -80.40 and a beta of 1.36.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.